{"id":22728,"date":"2020-09-28T10:11:26","date_gmt":"2020-09-28T08:11:26","guid":{"rendered":"https:\/\/kymos.com\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/"},"modified":"2026-03-04T21:10:26","modified_gmt":"2026-03-04T20:10:26","slug":"kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group","status":"publish","type":"post","link":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/","title":{"rendered":"Kymos i Prolytic es fusionen per esdevenir Kymos Group"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1170px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:10px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><h3 class=\"\" style=\"--fontsize: 17; line-height: 1.67; --minfontsize: 17;\" data-fontsize=\"17\" data-lineheight=\"28.39px\"><span style=\"font-size: 14pt;\"><strong>Amb la CRO alemanya unint-se al grup europeu, Kymos refor\u00e7ar\u00e0 la seva activitat en el mercat de productes biol\u00f2gics i ter\u00e0pies avan\u00e7ades i ampliar\u00e0 la seva cartera de serveis, oferint tres seus locals a Europa<\/strong><\/span><\/h3>\n<div class=\"blog-content\">\n<div class=\"field field-name-body field-type-text-with-summary field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item even\">\n<p><span style=\"font-size: 14pt;\"><strong>Barcelona, Espanya, i Frankfurt, Alemanya, 28 de setembre de 2020<\/strong> \u2013 <a href=\"https:\/\/kymos.com\/ca\/kymos\/\" data-wpel-link=\"internal\">Kymos S.L<\/a>. i <a href=\"https:\/\/kymos.com\/ca\/prolitic\/\" data-wpel-link=\"internal\">Prolytic GmbH<\/a> anuncien avui la finalitzaci\u00f3 d&#8217;una fusi\u00f3 estrat\u00e8gica exitosa per integrar Prolytic al Kymos Group i oferir serveis de valor afegit a empreses biofarmac\u00e8utiques de tot el m\u00f3n, amb una soluci\u00f3 veritablement paneuropea en un entorn empresarial en r\u00e0pida evoluci\u00f3. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">La combinaci\u00f3 d&#8217;experi\u00e8ncia permetr\u00e0 a les empreses ampliar la seva cartera amb una selecci\u00f3 \u00fanica de serveis per a mol\u00e8cules petites i grans innovadores, gen\u00e8rics, biosimilars, anticossos, biomarcadors, ADA (anticossos anti-f\u00e0rmac), ADC (conjugats antic\u00f2s-f\u00e0rmac), hormones, enzims i \u00e0cids nucleics. Tamb\u00e9 intensificaran la seva activitat en el mercat de ter\u00e0pies avan\u00e7ades. L&#8217;inter\u00e8s per les prote\u00efnes recombinants i per les ter\u00e0pies cel\u00b7lulars i g\u00e8niques avan\u00e7ades est\u00e0 actualment en auge a Europa i a tot el m\u00f3n. Prolytic ha adquirit experi\u00e8ncia en tecnologies d&#8217;ARNm, que s&#8217;utilitzen en algunes de les vacunes contra la Covid-19 m\u00e9s avan\u00e7ades que s&#8217;estan desenvolupant a Europa.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Les dues empreses, juntament amb Pharmaprogress, una filial de Kymos Group a It\u00e0lia, comparteixen un comprom\u00eds amb la qualitat i una dedicaci\u00f3 a la innovaci\u00f3. Tot i que els clients tindran acc\u00e9s a una gamma m\u00e9s \u00e0mplia de serveis certificats GMP\/GLP i conformes amb GCP, continuaran obtenint un servei personalitzat, adaptat i genu\u00efnament flexible, in\u00e8dit en qualsevol altra CRO de la seva mida. Kymos i Prolytic tenen una comprensi\u00f3 multidisciplin\u00e0ria de tot el proc\u00e9s de desenvolupament i fabricaci\u00f3 farmac\u00e8utica, des de les fases de desenvolupament i cl\u00edniques fins a l&#8217;aprovaci\u00f3 final i els estudis post-comercialitzaci\u00f3, proporcionant seguretat i fiabilitat log\u00edstica. La fusi\u00f3 millorar\u00e0 la capacitat de l&#8217;empresa per reaccionar encara m\u00e9s r\u00e0pidament a les necessitats espec\u00edfiques dels seus clients globals.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u201cEl mercat actual vol prove\u00efdors de servei complet i solucions integrals. Amb aquesta fusi\u00f3 podrem pensar globalment i actuar localment, proporcionant als nostres clients un servei fiable, de confian\u00e7a i molt millorat,\u201d<\/em> va dir la Dra. Dorothee Krone, directora general de Prolytic. <em>\u201cLes empreses petites i mitjanes se senten c\u00f2modes treballant amb nosaltres. Kymos ens pot ajudar a cobrir tot el cicle de les ci\u00e8ncies de la vida i ara podem oferir una gamma de serveis molt m\u00e9s diversa del que mai hav\u00edem pogut fer en el passat.\u201d<\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u201cEl coneixement que Prolytic t\u00e9 sobre l&#8217;ADN i l&#8217;ARN \u00e9s un element cient\u00edfic clau del mercat de serveis de ter\u00e0pies avan\u00e7ades en el qual Kymos est\u00e0 entrant,\u201d<\/em> va dir el Sr. Joan Puig de Dou, CEO de Kymos. <em>\u201cLa fusi\u00f3 ens d\u00f3na l&#8217;oportunitat d&#8217;augmentar la nostra oferta de serveis, enfortir el mercat de ter\u00e0pies emergents i crear una empresa multinacional i multidisciplin\u00e0ria. Estem molt il\u00b7lusionats amb aquesta nova fase en la hist\u00f2ria de l&#8217;empresa.\u201d<\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Amb aquesta fusi\u00f3, Kymos t\u00e9 ara tres seus a Europa: a Barcelona (Espanya), Ancona (It\u00e0lia) i Frankfurt (Alemanya). La seu italiana \u00e9s el resultat de la fusi\u00f3 del 2016 amb Pharmaprogress SRL. Segons l&#8217;acord, els noms de les empreses es mantindran sense canvis. A la seu alemanya de Prolytic, la direcci\u00f3 actual es mantindr\u00e0, mentre que el nombre de personal augmentar\u00e0. Es posar\u00e0 en marxa un pla d&#8217;inversi\u00f3 per adquirir equips d&#8217;\u00faltima generaci\u00f3.    <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Despr\u00e9s de refor\u00e7ar la seva ja destacada pres\u00e8ncia a la UE, el grup europeu tindr\u00e0 com a objectiu expandir-se a la regi\u00f3 \u00c0sia-Pac\u00edfic, alhora que obre noves \u00e0rees terap\u00e8utiques prometedores.<\/span><\/p>\n<p><strong style=\"font-size: 14pt; color: var(--body_typography-color); font-family: var(--body_typography-font-family); font-style: var(--body_typography-font-style,normal); letter-spacing: var(--body_typography-letter-spacing);\">Sobre Prolytic <\/strong><\/p>\n<p><span style=\"font-size: 14pt;\">Prolytic GmbH \u00e9s un expert en bioan\u00e0lisi i farmacocin\u00e8tica amb capacitats especialitzades de recerca per contracte en bioan\u00e0lisi i avaluacions farmacocin\u00e8tiques sota GLP i GCP.<\/span><br \/><span style=\"font-size: 14pt;\">Ofereix una gamma de serveis sofisticats en el desenvolupament i validaci\u00f3 de m\u00e8todes anal\u00edtics per a l&#8217;an\u00e0lisi i quantificaci\u00f3 de mol\u00e8cules petites, prote\u00efnes, anticossos i ant\u00edgens, ADAs (anticossos anti-f\u00e0rmac), biomarcadors i biosimilars i enzims intactes, aix\u00ed com an\u00e0lisi de mostres per a estudis precl\u00ednics i cl\u00ednics. Prolytic pot realitzar an\u00e0lisis qualitatives o quantitatives de f\u00e0rmacs i metab\u00f2lits en sang, plasma, orina, teixits o altres matrius biol\u00f2giques. A m\u00e9s, tamb\u00e9 pot dur a terme avaluacions farmacocin\u00e8tiques compartimentals i no compartimentals. Com a innovador, Prolytic \u00e9s l\u00edder en projectes de cooperaci\u00f3 de recerca finan\u00e7ats per l&#8217;estat en el camp del desenvolupament de biomarcadors d&#8217;ARN i ter\u00e0pies avan\u00e7ades.   <\/span><br \/><span style=\"font-size: 14pt;\">Creada el 2002 i amb seu a Frankfurt, Prolytic compta amb 17 empleats i 1.000 metres quadrats d&#8217;instrumentaci\u00f3 d&#8217;\u00faltima generaci\u00f3.<\/span><\/p>\n<p><span style=\"font-size: 18.6667px;\"><a href=\"https:\/\/kymos.com\/ca\/prolitic\/\" data-wpel-link=\"internal\">kymos.com\/prolytic<\/a><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Sobre Kymos<\/strong><\/span><br \/><span style=\"font-size: 14pt;\">Kymos S.L. \u00e9s un l\u00edder mundial i un dels deu principals prove\u00efdors globals de serveis de proves de biosimilars, amb anys d&#8217;experi\u00e8ncia en productes biol\u00f2gics, mol\u00e8cules petites i serveis integrals tant en CMC com en bioan\u00e0lisi. Kymos, una organitzaci\u00f3 de laboratori per contracte europea certificada GLP\/GMP, conforme amb GCP i inspeccionada per l&#8217;EMA i la FDA, especialitzada en bioan\u00e0lisi i CMC, proporciona estudis complets de bioequival\u00e8ncia, incloent-hi biowavers per a DP t\u00f2pics, bioan\u00e0lisi de mol\u00e8cules petites i grans, ADA, proves d&#8217;alliberament de lots per a assajos precl\u00ednics i cl\u00ednics a Europa. Kymos tamb\u00e9 ofereix serveis de CMC per al desenvolupament de m\u00e8todes, caracteritzaci\u00f3, comparabilitat de biosimilars, a m\u00e9s d&#8217;anys d&#8217;experi\u00e8ncia amb clients biofarmac\u00e8utics a tot el m\u00f3n.  <\/span><br \/><span style=\"font-size: 14pt;\">Creada el 2001 i amb seu a Barcelona, Kymos compta amb 110 empleats i 3.000 m2 d&#8217;instal\u00b7lacions, amb instruments d&#8217;\u00faltima generaci\u00f3. La filial italiana t\u00e9 20 empleats addicionals i uns 1.000 m2 d&#8217;instal\u00b7lacions. S&#8217;espera que la facturaci\u00f3 conjunta de les tres empreses superi els 13 milions d&#8217;euros (15,1 milions de d\u00f2lars) el 2020.  <\/span><br \/><span style=\"font-size: 14pt;\"><a href=\"https:\/\/kymos.com\/ca\/\" data-wpel-link=\"internal\">Kymos<\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6,"featured_media":14962,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[107,106],"tags":[],"class_list":["post-22728","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-kymos-group-ca","category-novetats"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymos i Prolytic es fusionen per esdevenir Kymos Group | Kymos<\/title>\n<meta name=\"description\" content=\"Kymos S.L. i Prolytic GmbH anuncien una fusi\u00f3 estrat\u00e8gica exitosa per integrar Prolytic al Kymos Group.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymos i Prolytic es fusionen per esdevenir Kymos Group | Kymos\" \/>\n<meta property=\"og:description\" content=\"Kymos S.L. i Prolytic GmbH anuncien una fusi\u00f3 estrat\u00e8gica exitosa per integrar Prolytic al Kymos Group.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-28T08:11:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T20:10:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"494\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"Kymos i Prolytic es fusionen per esdevenir Kymos Group\",\"datePublished\":\"2020-09-28T08:11:26+00:00\",\"dateModified\":\"2026-03-04T20:10:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/\"},\"wordCount\":1167,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"articleSection\":[\"Kymos Group\",\"Not\u00edcies\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/\",\"name\":\"Kymos i Prolytic es fusionen per esdevenir Kymos Group | Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"datePublished\":\"2020-09-28T08:11:26+00:00\",\"dateModified\":\"2026-03-04T20:10:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Kymos S.L. i Prolytic GmbH anuncien una fusi\u00f3 estrat\u00e8gica exitosa per integrar Prolytic al Kymos Group.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"width\":900,\"height\":494},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/ca\\\/inici\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymos i Prolytic es fusionen per esdevenir Kymos Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymos i Prolytic es fusionen per esdevenir Kymos Group | Kymos","description":"Kymos S.L. i Prolytic GmbH anuncien una fusi\u00f3 estrat\u00e8gica exitosa per integrar Prolytic al Kymos Group.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/","og_locale":"ca_ES","og_type":"article","og_title":"Kymos i Prolytic es fusionen per esdevenir Kymos Group | Kymos","og_description":"Kymos S.L. i Prolytic GmbH anuncien una fusi\u00f3 estrat\u00e8gica exitosa per integrar Prolytic al Kymos Group.","og_url":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/","og_site_name":"Kymos","article_published_time":"2020-09-28T08:11:26+00:00","article_modified_time":"2026-03-04T20:10:26+00:00","og_image":[{"width":900,"height":494,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"Escrit per":"Joan Puig de Dou","Temps estimat de lectura":"6 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"Kymos i Prolytic es fusionen per esdevenir Kymos Group","datePublished":"2020-09-28T08:11:26+00:00","dateModified":"2026-03-04T20:10:26+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/"},"wordCount":1167,"image":{"@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","articleSection":["Kymos Group","Not\u00edcies"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/","url":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/","name":"Kymos i Prolytic es fusionen per esdevenir Kymos Group | Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","datePublished":"2020-09-28T08:11:26+00:00","dateModified":"2026-03-04T20:10:26+00:00","author":{"@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Kymos S.L. i Prolytic GmbH anuncien una fusi\u00f3 estrat\u00e8gica exitosa per integrar Prolytic al Kymos Group.","breadcrumb":{"@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","width":900,"height":494},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/ca\/news\/kymos-i-prolytic-es-fusionen-per-convertir-se-en-kymos-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/ca\/inici\/"},{"@type":"ListItem","position":2,"name":"Kymos i Prolytic es fusionen per esdevenir Kymos Group"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/ca\/#website","url":"https:\/\/kymos.com\/ca\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/ca\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/comments?post=22728"}],"version-history":[{"count":3,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22728\/revisions"}],"predecessor-version":[{"id":35220,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22728\/revisions\/35220"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media\/14962"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media?parent=22728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/categories?post=22728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/tags?post=22728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}